Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026 Aspire Biopharma (Nasdaq:ASBP) subsidiary Buzz Bomb Caffeine Company will feature its flagship product BUZZ BOMB™ at The Health & Fitness Show, March 16-18, 2026 in San Diego.BUZZ BOMB™ is a 50mg single-serving dry powder stick pack designed to be sprinkled under the tongue for rapid caffeine absorption, portable dosing, and natural flavors with organic, non-GMO caffeine.

#ASBP #ASBPW Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026

www.stocktitan.net/news/ASBP/aspire-biophar...

Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack Aspire Biopharma (Nasdaq: ASBP) subsidiary Buzz Bomb Caffeine Company is launching a new BUZZ BOMB Convenience Store Pack, a six-count "Fruit Blast" offering with two each of Tropical Fruit, Mixed Berry, and Peach Mango.Each single-serving stick contains 50mg fast-acting dry powder caffeine delivered under the tongue; rollout begins in select convenience stores starting in May.

#ASBP #ASBPW Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack

www.stocktitan.net/news/ASBP/aspire-biophar...

New under-the-tongue alprazolam powder aims to calm anxiety faster Faster anxiety relief is goal as Aspire and Microsize develop a sublingual alprazolam powder, with Phase 1 trials planned for mid-2026 and a $55.8B market.

#ASBP #ASBPW Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief

www.stocktitan.net/news/ASBP/aspire-biophar...

Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity Strategic inventory of 100,000 20-packs now available to meet increasing demand for rapid-onset sublingual caffeine technologyESTERO, FL / ACCESS Newswire / January 22, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP), a leader in innovative patent-pending sublingual delivery technologies,

#ASBP #ASBPW Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity

www.stocktitan.net/news/ASBP/aspire-biophar...

Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign Aspire Biopharma (NASDAQ:ASBP) announced a comprehensive brand redesign for its flagship caffeine product, BUZZ BOMB™ on January 21, 2026. The initiative includes a new logo, a mobile‑optimized e-commerce website at https://buzzbombcaffeine.com, and redesigned packaging with a vibrant aesthetic to emphasize rapid, sustained focus and sublingual delivery.The website offers a streamlined shopping experience, product information, promotions, and educational content. Management says the redesign aims to improve customer engagement, showcase the product's capabilities, and position BUZZ BOMB for growth.

#ASBP #ASBPW Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign

www.stocktitan.net/news/ASBP/aspire-biophar...

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief Aspire Biopharma (NASDAQ:ASBP) filed a provisional patent application for a first-ever sublingual powder formulation of alprazolam, aiming to improve bioavailability and accelerate onset versus oral tablets. The filing covers a sublingual delivery system designed to absorb alprazolam under the tongue to bypass first-pass metabolism and potentially shorten onset from about 30 minutes to minutes.The company said it plans a Phase 1 clinical trial in mid-2026 and intends to pursue commercialization via the FDA 505(b)(2) pathway. Aspire framed this program as part of a broader pipeline of reformulated approved therapeutics targeting patients needing rapid relief or who have difficulty swallowing.

#ASBP #ASBPW Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief

www.stocktitan.net/news/ASBP/aspire-biophar...

Aspire Biopharma Announces Reverse Stock Split Aspire Biopharma (NASDAQ:ASBP) announced a 1-for-40 reverse stock split of its common stock effective 12:01 a.m. ET on January 16, 2026, with split-adjusted trading beginning at market open on January 16, 2026. The split reduces outstanding shares from approximately 158.8 million to approximately 4.0 million ASBP with a new CUSIP 738920 206. The reverse split is being implemented to help ensure compliance with The Nasdaq Capital Market's minimum bid price requirement. Fractional shares will be rounded up to the nearest whole share at the participant level; no fractional shares will be issued.

#ASBP #ASBPW Aspire Biopharma Announces Reverse Stock Split

www.stocktitan.net/news/ASBP/aspire-biophar...

4 High Volatility Penny Stocks Technical Analysis | ASBP, OCG, GPUS & LUCY Stock Forecast YouTube video by Hisseseven

youtu.be/J4iS_5fHREs #StockMarket
#TechnicalAnalysis
#PennyStocks
#DayTrading
#SwingTrading
#ASBP
#OCG
#GPUS
#LUCY
#HighVolatilityStocks
#StockTrading
#NASDAQStocks
#Rubio
#RepublicanPolitics
#USMilitaryStrategy
#GreenlandPolicy
#RHOSLC
#UkraineSupport

📢 Stocks Trending NOW: #SNDK #MU #VTYX #ISRG #GME #GLUE #MBLY #LUCY #ASBP #AMOD

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements Aspire Biopharma (Nasdaq: ASBP) received a notice from the Nasdaq Hearings Panel granting an extension to continue its Nasdaq listing, subject to conditions after the Company's transfer to the Nasdaq Capital Market.The company will transfer its common stock listing effective at market open on December 15, 2025, retain the symbol ASBP, and must demonstrate compliance with the Bid Price Rule (Rule 5550(a)(2)) by January 30, 2026 and the Equity Rule (Rule 5550(b)(1)) by February 17, 2026. Management said it expects to cure the bid-price and market-value deficiencies and is working to recapitalize the balance sheet.

#ASBP #ASBPW Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

www.stocktitan.net/news/ASBP/aspire-biophar...

Aspire Biopharma (Nasdaq: ASBP) targets H1 2026 NDA after fast-acting aspirin data Aspire advances its sublingual aspirin toward an H1 2026 NDA, scales BUZZ BOMB with a 2M-serving order, and plans up to 10 new patents by Q1 2026.

#ASBP #ASBPW Aspire Biopharma Provides Q3 2025 Business Update

www.stocktitan.net/news/ASBP/aspire-biophar...

Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member Aspire Biopharma (NASDAQ:ASBP) announced the November 4, 2025 hire of Mark J. Jaroszeski, PhD to its scientific team. Dr. Jaroszeski is a tenured professor of Medical Engineering at the University of South Florida with a PhD in Engineering Science and a long record in DNA and drug delivery, including early in vivo electroporation work, 34 U.S. patents, and leadership roles in academic and startup research.The company said his expertise will support development and optimization of Aspire's patent-pending sublingual delivery technology and help extend the platform across its pipeline of generic medicines.

#ASBP #ASBPW Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member

www.stocktitan.net/news/ASBP/aspire-bio-pha...

📢 Stocks Trending NOW: #TSLA #MSTR #CDTX #COIN #NVDA #IVVD #AVXL #WMT #ASBP #HOOD

#ASBP #ASBPW Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin

www.stocktitan.net/news/ASBP/aspire-biophar...

Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform ESTERO, FLORIDA / ACCESS Newswire / October 6, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery technology, today announced the filing of an omnibus patent application with the U.S. Patent and Trademark

#ASBP #ASBPW Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform

www.stocktitan.net/news/ASBP/aspire-biophar...

🚨 Hot take on #ASBP! Trading at $0.38, Aspire Biopharma shows mixed signals: short-term bullish momentum but potential resistance ahead. High volume hints at strategic moves, yet delisting risks loom. Consider a short position with targets at $0.35 & $0.32. Stay sharp! 📉 #FeetrAI

🚨 FeetrAI Alert: #ASBP is in the spotlight! Trading at $0.3738, Aspire Biopharma shows mixed signals. Short-term bullishness meets potential resistance. Low volume & bearish MACD suggest caution. Consider a SHORT at $0.375, targeting $0.36 & $0.35. Stop loss: $0.39. 📉 #StockMarket #FeetrAI

🚨 Hot Stock Alert: #ASBP is on the move with trading volume soaring! 📈 Despite mixed signals, a sharp drop from $0.47 to $0.3742 hints at profit-taking or delisting fears. Consider shorting at $0.38, targeting $0.35 & $0.32. Stay alert for updates! #StockWatch #FeetrAI

🚀 Exciting times for #ASBP! With bullish momentum and key moving averages in its favor, Aspire Biopharma is poised for gains. Positive trial results and market optimism add fuel. Consider entering at $0.52 with targets at $0.55 & $0.58. Stop loss: $0.48. 📈 #FeetrAI

🚀 Exciting times for #ASBP! Trading at $0.5197, Aspire Biopharma shows bullish momentum with strong technicals: 8-day EMA at $0.4863 & RSI at 65.9. Volume spikes hint at investor interest in their aspirin trials. Consider a LONG position targeting $0.55 & $0.58. 📈 #BiotechBoom

🚀 Exciting times for #ASBP! Trading at $0.5041, Aspire Biopharma shows bullish momentum with a 10-day SMA of $0.4323 and 8-day EMA of $0.4692. RSI above 60 hints at growth potential. Positive MACD & recent trial success add to the optimism. Target: $0.52-$0.54. 📈 #FeetrAI

Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World Aspire Biopharma (NASDAQ:ASBP) has successfully launched its innovative pre-workout supplement BUZZ BOMB™ at FitCon and FitExpo, distributing over 30,000 sample packs to attendees. The product features a unique sublingual delivery technology with 50mg of caffeine in four flavors: Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha.The product differentiates itself through rapid absorption (under 2 minutes vs. traditional 20-30 minutes), convenient single-use packets, and precise energy management. Notable fitness figures including UFC fighter Bobby Maximus and MMA champion Brandon Copeland have provided positive testimonials. The product is now available for purchase through the company's e-commerce website buzzbomb.buzz.

#ASBP #ASBPW Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

www.stocktitan.net/news/ASBP/aspire-biophar...

Game-Changing Pre-Workout Supplement Delivers Instant Energy Without Water Mixing - BUZZ BOMB Hits Market First-ever sublingual pre-workout delivers 50mg caffeine instantly, no mixing needed. Available in 4 flavors through new direct-to-consumer platform. See launch offers.

#ASBP #ASBPW Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement

www.stocktitan.net/news/ASBP/aspire-biophar...

Aspire Biopharma Holdings, Inc. Announces CEO Transition Aspire Biopharma Holdings (NASDAQ:ASBP) announced significant leadership changes, with Chairman Kraig Higginson appointed as interim CEO effective July 24, 2025, following Michael C. Howe's resignation from both CEO position and Board membership.The company also announced the immediate resignations of Board members Gary E. Stein and Barbara Sher. In a key appointment, Howard Doss, a seasoned financial executive with extensive experience at companies like PowerUp and Trade Health, has joined as Director and Chairman of the Audit Committee.Higginson, who previously served as CEO for four years, expressed commitment to executing the company's strategy focused on its drug delivery platform technology.

#ASBP #ASBPW Aspire Biopharma Holdings, Inc. Announces CEO Transition

www.stocktitan.net/news/ASBP/aspire-biophar...

Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World Aspire Biopharma Holdings (NASDAQ:ASBP) announced the launch of its new pre-workout supplement BUZZ BOMB™ at two major fitness conventions - FitCon in Salt Lake City (August 1-2) and FitExpo in Anaheim (August 2-3, 2025).The product features 50mg of caffeine delivered through sublingual nano technology, offering nearly instant energy through easy-to-use packets. As a Gold Sponsor at FitCon (20,000 attendees) and sponsor at FitExpo (33,000 attendees), BUZZ BOMB™ will receive prominent placement, extensive marketing exposure, and product sampling opportunities to all attendees.The company aims to disrupt the multi-billion-dollar pre-workout market with its innovative delivery system that provides immediate effects compared to traditional pre-workout supplements that require 20-30 minutes to activate.

#ASBP #ASBPW Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

www.stocktitan.net/news/ASBP/aspire-biophar...

Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement Aspire Biopharma Holdings (NASDAQ:ASBP) has announced positive consumer feedback for its new pre-workout supplement BUZZ BOMB™. The product features a patent-pending sublingual delivery technology with 50mg of caffeine designed for rapid absorption and immediate effect.The company has completed initial production in four flavors (Tropical Fruit, Mixed Berry, Peach Mango, and Mocha Coffee) and plans to launch at major fitness conventions in August. BUZZ BOMB™ is packaged in single-serving packets and targets the pre-workout supplement market, projected to reach $27.97 billion by 2030.CEO Michael Howe indicated this launch represents the first step in Aspire's strategy to leverage its sublingual nano technology, with plans to introduce additional nutraceutical and supplement products while exploring licensing opportunities.

#ASBP #ASBPW Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement

www.stocktitan.net/news/ASBP/aspire-biophar...

Novel Fast-Acting Aspirin Shows Promise: Phase 1 Trial Completion Sets Stage for Q3 Heart Attack Treatment Data New sublingual aspirin formulation completes Phase 1 dosing, targeting faster heart attack intervention. Key efficacy data expected Q3 2025. See development timeline.

#ASBP #ASBPW Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

www.stocktitan.net/news/ASBP/aspire-biophar...